Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02613117 · ClinicalTrials.gov registry record · NA

Research on Oral Tolerability and Product Application/Response of Two Oxalate Products for Dental Patients With Risk of Dentinal Hypersensitivity

A NA study, sponsored by Procter and Gamble.

Completed
Registry status
NA
Development phase
104
Enrollment target

NCT02613117: Completed NA study, sponsored by Procter and Gamble.

NCT02613117 is a NA study that has completed, run by Procter and Gamble. The registered enrollment target is 104 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02613117, a NA study, has completed, sponsored by Procter and Gamble.

COMPLETED
Registry status
NA
Development phase
104 participants
Enrollment target

Study Summary

This study will assess the oral tolerability and immediate post-treatment safety of topical application for two marketed oxalate products as initial care in dental patients to treat or prevent tooth sensitivity pain that may be attributed to dentinal hypersensitivity.

Primary Outcome

Questionnaire indicating the frequencies of using various oral hygiene products by subjects at 5 different dental practices.

Interventions

  • DRUG Stannous fluoride paste
  • DEVICE Potassium Oxalate Gel
  • DEVICE Potassium Oxalate Liquid

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2015-11
Est. Completion 2016-06
Phase NA
Procter and Gamble

70 total trials

What the finished NCT02613117 record still lists

NCT02613117 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 3 interventions - of which Stannous fluoride paste is the first listed.

NCT02613117 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02613117 about?

NCT02613117 is a clinical study titled "Research on Oral Tolerability and Product Application/Response of Two Oxalate Products for Dental Patients With Risk of Dentinal Hypersensitivity". This study will assess the oral tolerability and immediate post-treatment safety of topical application for two marketed oxalate products as initial care in dental patients to treat or prevent tooth sensitivity pain that may be attributed to dentinal hypersensitivity.

What is the current status of trial NCT02613117?

This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2015-11. Estimated completion is 2016-06.

What interventions are being tested in trial NCT02613117?

The interventions under investigation include: Stannous fluoride paste (DRUG), Potassium Oxalate Gel (DEVICE), Potassium Oxalate Liquid (DEVICE).

Who is sponsoring clinical trial NCT02613117?

This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02613117's enrollment target sits among peer trials

104 836th of 2000 higher than 1,164 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02613117, the US trial registry maintained by the National Library of Medicine. NCT02613117 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.